REG - BiVictriX Therapcts. - Patent Granted in Japan

Bivictrix TherapeuticsAnnouncement

15/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231115:nRSO4521Ta&default-theme=true

RNS Number : 4521T  BiVictriX Therapeutics PLC  15 November 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

 

Patent Granted in Japan Providing Further Broad Protection for BVX001

 

·    Provides broad protection for lead product, BVX001, in a market where
AML is the most common acute leukaemia, accounting for c.70% of all myeloid
leukaemias

·    Builds upon the recent US patent grant, providing strong IP position
in two key global markets

·    Prosecution for the patent family currently being pursued in a
further six global jurisdictions

 

Alderley Park, 15 November 2023 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a differentiated approach to develop
novel, next-generation anti-cancer precision Antibody Drug Conjugates,
offering substantially improved cancer cell selectivity and therapeutic
activity, announces today that the Japanese Patent Office ("JPO") has granted
a patent providing broad protection for the Company's lead asset, BVX001.

 

This follows the Company's announcement on 23 August 2023
(https://bivictrix.com/news/us-patent-granted-providing-broad-protection-for-bvx001/)
regarding the grant by the United  States Patent and Trademark Office. This
latest patent grant from the JPO is part of the Company's strategy of broad
protection for BVX001. The claims granted within this patent (patent number
7337824), which belongs to the wider patent family "Therapy", are currently
being prosecuted in a further six jurisdictions worldwide to provide ultimate
broad protection for BVX001 at the highest antigen level.

 

Tiffany Thorn, CEO of BiVictriX commented: "The approval of this patent in
Japan, which follows swiftly after the granting of our patent in the US, puts
BiVictriX in a strong IP position in two key global markets.  With plans to
prosecute in a further six global jurisdictions, we are building strong
protection for our lead therapeutic asset, at the broadest level, enhancing
the value of BVX001 as we prepare for first in human studies and refine the
optimal drug development and commercialisation strategy."

 

 

 ENDS

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman             Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)      Tel: +44 (0) 20 3470 0470
 David Hignell, Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)             Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 ICR Consilium
 Mary-Jane Elliott, Namrata Taak,                     Tel: +44 (0) 20 3709 5700

 Max Bennett, Emmalee Hoppe                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific
Bi-Cygni® fingerprints, which enable the Company to target a diverse array of
different cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug Conjugate
therapeutic design, to develop more effective and safer therapeutics to target
cancers that are expected to constitute orphan indications and areas of high
unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFVDLVLSLIV